Lactococcus lactis carrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis.

M. ZURITA-TURK; S. DEL CARMEN; A. CG SANTOS; V.B. PEREIRA; D.C. CARA; S.Y. LECLERQ; A. DE MORENO DE LEBLANC; V. AZEVEDO; JM. CHATEL; J.G. LEBLANC; A. MIYOSHI

BMC BIOTECHNOLOGY

BIOMED CENTRAL LTD

Lugar: Londres; Año: 2014 vol. 14 p. 1 - 11

1472-6750

Inflammatory bowel diseases (IBD) are intestinal disorders characterized by inflammation in the gastrointestinal tract. Interleukin-10 is one of the most important anti-inflammatory cytokines involved in the intestinal immune system and because of its role in down regulating inflammatory cascades, its potential for IBD therapy is under study. We previously presented the development of an invasive strain of Lactococcus lactis (L. lactis) producing Fibronectin Binding Protein A (FnBPA) which was capable of delivering, directly to host cells, a eukaryotic DNA expression vector coding for IL-10 of Mus musculus (pValac:il-10) and diminish inflammation in a trinitrobenzene sulfonic acid (TNBS)-induced mouse model of intestinal inflammation. As a new therapeutic strategy against IBD, the aim of this work was to evaluate the therapeutic effect of two L. lactis strains (the same invasive strain evaluated previously and the wild-type strain) carrying the therapeutic pValac:il-10 plasmid in the prevention of inflammation in a dextran sodium sulphate (DSS)-induced mouse model.